

CITATION REPORT

List of articles citing

Cytogenetic abnormalities correlate with the plasma cell labeling index and extent of bone marrow involvement in myeloma

DOI: 10.1016/s0165-4608(99)00009-6

Cancer Genetics and Cytogenetics, 1999, 113, 73-7.

Source: <https://exaly.com/paper-pdf/30555688/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
84	Cytogenetic abnormalities in multiple myeloma. <i>Hematology/Oncology Clinics of North America</i> , 1999 , 13, 1169-80, viii	3.1	21
83	Prognostic factors in multiple myeloma. <i>Hematology/Oncology Clinics of North America</i> , 1999 , 13, 1295-314, xi	3.1	81
82	Chromosomes 1 and 5 harbor plasmacytoma progressor genes in mice. <i>Genes Chromosomes and Cancer</i> , 2000 , 29, 70-4	5	12
81	Hypodiploidy is a major prognostic factor in multiple myeloma. <i>Blood</i> , 2001 , 98, 2229-38	2.2	303
80	Laboratory correlates in multiple myeloma: how useful for prognosis?. <i>Blood Reviews</i> , 2001 , 15, 97-102	11.1	7
79	Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy. <i>Leukemia</i> , 2001 , 15, 981-6	10.7	108
78	Waldenström macroglobulinemia neoplastic cells lack immunoglobulin heavy chain locus translocations but have frequent 6q deletions. <i>Blood</i> , 2002 , 100, 2996-3001	2.2	169
77	Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. <i>Blood</i> , 2002 , 99, 3735-41	2.2	255
76	Cytogenetic features of multiple myeloma: impact of gender, age, disease phase, culture time, and cytokine stimulation. <i>European Journal of Haematology</i> , 2002 , 68, 345-53	3.8	18
75	Long-term follow up with conventional cytogenetics and band 13q14 interphase/metaphase in situ hybridization monitoring in monoclonal gammopathies of undetermined significance. <i>British Journal of Haematology</i> , 2002 , 118, 545-9	4.5	11
74	Multiple myeloma: evolving genetic events and host interactions. <i>Nature Reviews Cancer</i> , 2002 , 2, 175-87	31.3	654
73	Both chromosome 13 abnormalities by metaphase cytogenetics and deletion of 13q by interphase FISH only are prognostically relevant in multiple myeloma. <i>European Journal of Haematology</i> , 2003 , 71, 179-83	3.8	28
72	Telomere shortening in patients with plasma cell disorders. <i>European Journal of Haematology</i> , 2003 , 71, 334-40	3.8	25
71	Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma. <i>Immunological Reviews</i> , 2003 , 194, 96-104	11.3	112
70	Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. <i>Leukemia</i> , 2003 , 17, 427-36	10.7	186
69	Many and multiple myeloma(s). <i>Leukemia</i> , 2003 , 17, 1943-4	10.7	21
68	The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple myeloma: an evidence-based review. <i>Biology of Blood and Marrow Transplantation</i> , 2003 , 9, 4-37	7.7	76

67	Advances in Biology and Therapy of Multiple Myeloma. <i>Hematology American Society of Hematology Education Program</i> , 2003 , 2003, 248-278	3.1	52
66	Practical radiology of plasmacytoma and multiple myeloma. <i>South African Journal of Radiology</i> , 2003 , 7, 22-25	0.6	
65	Clinical Significance of Cytogenetics in Multiple Myeloma and Chronic Lymphocytic Leukemia. <i>Laboratory Medicine</i> , 2004 , 35, 685-692	1.6	
64	Signaling, drugs and apoptosis of myeloma cells. <i>Cancer Biology and Therapy</i> , 2004 , 3, 195-6	4.6	1
63	Genetics and cytogenetics of multiple myeloma: a workshop report. <i>Cancer Research</i> , 2004 , 64, 1546-58	10.1	560
62	Strategies to improve the outcome of stem cell transplantation in multiple myeloma. <i>The Hematology Journal</i> , 2004 , 5, 9-23		11
61	High frequencies of chromosomal aberrations in multiple myeloma and monoclonal gammopathy of undetermined significance in direct chromosome preparation. <i>British Journal of Haematology</i> , 2004 , 126, 487-94	4.5	10
60	Molecular monitoring of minimal residual disease in patients with multiple myeloma. <i>Hematology</i> , 2004 , 9, 17-33	2.2	12
59	Advances in biology of multiple myeloma: clinical applications. <i>Blood</i> , 2004 , 104, 607-18	2.2	496
58	Prognostic and biologic significance of chromosomal imbalances assessed by comparative genomic hybridization in multiple myeloma. <i>Blood</i> , 2004 , 104, 2661-6	2.2	81
57	Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma. <i>Leukemia</i> , 2005 , 19, 275-8	10.7	97
56	Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics. <i>Genes Chromosomes and Cancer</i> , 2005 , 44, 194-203	5	78
55	Prognostic impact of cytogenetic aberrations in patients with multiple myeloma or monoclonal gammopathy of unknown significance. <i>Hematological Oncology</i> , 2005 , 23, 102-7	1.3	7
54	Clinical significance of cytogenetics and interphase fluorescence in situ hybridization analysis in newly diagnosed multiple myeloma in Taiwan. <i>Annals of Oncology</i> , 2005 , 16, 1530-8	10.3	21
53	Targeting signalling pathways for the treatment of multiple myeloma. <i>Expert Opinion on Therapeutic Targets</i> , 2005 , 9, 359-81	6.4	32
52	Molecular pathogenesis and a consequent classification of multiple myeloma. <i>Journal of Clinical Oncology</i> , 2005 , 23, 6333-8	2.2	435
51	Risk stratification of patients with newly diagnosed multiple myeloma: optimizing treatment based on pretreatment characteristics. <i>Clinical Lymphoma and Myeloma</i> , 2005 , 6, 200-7		5
50	Genetics of multiple myeloma. <i>Best Practice and Research in Clinical Haematology</i> , 2005 , 18, 525-36	4.2	10

49	Genetics and molecular profiling of multiple myeloma: novel tools for clinical management?. <i>European Journal of Cancer</i> , 2006 , 42, 1530-8	7.5	25
48	Paradoxical expression of INK4c in proliferative multiple myeloma tumors: bi-allelic deletion vs increased expression. <i>Cell Division</i> , 2006 , 1, 23	2.8	30
47	Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations. <i>Leukemia</i> , 2006 , 20, 807-13	10.7	112
46	Derivative (1;7)(q10;p10) in multiple myeloma. A sign of therapy-related hidden myelodysplastic syndrome. <i>Cancer Genetics and Cytogenetics</i> , 2006 , 167, 131-7		12
45	A transgenic mouse model of plasma cell malignancy shows phenotypic, cytogenetic, and gene expression heterogeneity similar to human multiple myeloma. <i>Cancer Research</i> , 2007 , 67, 4069-78	10.1	38
44	Treatment of Newly Diagnosed Multiple Myeloma Based on Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART): Consensus Statement. <i>Mayo Clinic Proceedings</i> , 2007 , 82, 323-341	6.4	119
43	Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. <i>Mayo Clinic Proceedings</i> , 2007 , 82, 323-41	6.4	123
42	Genetic events in the pathogenesis of multiple myeloma. <i>Best Practice and Research in Clinical Haematology</i> , 2007 , 20, 571-96	4.2	140
41	Review of molecular diagnostics in multiple myeloma. <i>Expert Review of Molecular Diagnostics</i> , 2007 , 7, 453-9	3.8	14
40	Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. <i>Leukemia</i> , 2007 , 21, 151-7	10.7	224
39	An internationally recognized uniform cytogenetic classification system is needed for multiple myeloma. <i>Leukemia</i> , 2007 , 21, 9-11	10.7	3
38	A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. <i>Leukemia</i> , 2007 , 21, 529-34	10.7	168
37	In vivo and in silico studies on single versus multiple transplants for multiple myeloma. <i>Cancer Science</i> , 2007 , 98, 734-9	6.9	6
36	Cell lines of hyperdiploid myeloma, are we there yet?. <i>British Journal of Haematology</i> , 2008 , 140, 579-80; author reply 580-1	4.5	2
35	Cell lines of hyperdiploid myeloma, are we there yet? [response to Chng & Fonseca. <i>British Journal of Haematology</i> , 2008 , 140, 580-581	4.5	
34	DIAGNOSIS AND GENETIC CLASSIFICATION OF MULTIPLE MYELOMA. 1-17		1
33	Prognostic significance of apoptotic index in multiple myeloma patients treated by conventional therapy and novel agents, thalidomide and bortezomib. <i>European Journal of Haematology</i> , 2009 , 83, 528-34	3.8	3
32	A tandem triplication, trp(1)(q21q32), in a patient with follicular lymphoma: a case study and review of the literature. <i>Cancer Genetics and Cytogenetics</i> , 2009 , 189, 127-31		8

31	An abnormal nonhyperdiploid karyotype is a significant adverse prognostic factor for multiple myeloma in the bortezomib era. <i>American Journal of Hematology</i> , 2010 , 85, 752-6	7.1	16
30	Correlation between array-comparative genomic hybridization-defined genomic gains and losses and survival: identification of 1p31-32 deletion as a prognostic factor in myeloma. <i>Leukemia</i> , 2010 , 24, 833-42	10.7	38
29	Plasma cell neoplasms. 244-265		
28	Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapies. <i>Mayo Clinic Proceedings</i> , 2010 , 85, 532-7	6.4	52
27	The prognostic significance of cytogenetics and molecular profiling in multiple myeloma. <i>Cancer Genetics</i> , 2011 , 204, 3-12	2.3	150
26	Multiple myeloma: current perspectives. <i>Clinics in Laboratory Medicine</i> , 2011 , 31, 699-724, x	2.1	6
25	1q triplication in hematologic malignancies. <i>Atlas of Genetics and Cytogenetics in Oncology and Haematology</i> , 2011 ,	2.3	
24	Cytokinetically quiescent (G0/G1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2. <i>Blood</i> , 2011 , 118, 5189-200	2.2	39
23	Efficacy of thalidomide- or lenalidomide-based therapy in proliferative multiple myeloma. <i>Leukemia</i> , 2011 , 25, 1195-7	10.7	7
22	Chronic hepatitis virus infection in patients with multiple myeloma: clinical characteristics and outcomes. <i>Clinics</i> , 2011 , 66, 2055-61	2.3	13
21	Plasma cell labeling index correlates with deletion of 13q14 in multiple myeloma. <i>Leukemia and Lymphoma</i> , 2011 , 52, 260-4	1.9	3
20	Risk stratification of plasma cell neoplasm: insights from plasma cell-specific cytoplasmic immunoglobulin fluorescence in situ hybridization (cIg FISH) vs. conventional FISH. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012 , 12, 366-74	2	6
19	Fluorescence in situ hybridization analysis of chromosome aberrations in 60 Chinese patients with multiple myeloma. <i>Medical Oncology</i> , 2012 , 29, 2200-6	3.7	8
18	The impact of frontline risk-adapted strategy on the overall survival of patients with newly diagnosed multiple myeloma: an analysis of the Singapore multiple myeloma study group. <i>European Journal of Haematology</i> , 2012 , 89, 136-44	3.8	5
17	The impact of upfront versus sequential use of bortezomib among patients with newly diagnosed multiple myeloma (MM): a joint analysis of the Singapore MM Study Group and the Korean MM Working Party for the Asian myeloma network. <i>Leukemia Research</i> , 2013 , 37, 1070-6	2.7	12
16	TRIM13 (RFP2) downregulation decreases tumour cell growth in multiple myeloma through inhibition of NF Kappa B pathway and proteasome activity. <i>British Journal of Haematology</i> , 2013 , 162, 210-20	4.5	16
15	CD38 ligation in peripheral blood mononuclear cells of myeloma patients induces release of protumorigenic IL-6 and impaired secretion of IFN γ cytokines and proliferation. <i>Mediators of Inflammation</i> , 2013 , 2013, 564687	4.3	8
14	Amplification of 1q21 and other abnormalities in multiple myeloma patients from a tertiary hospital in Singapore. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2014 , 30, 253-8	0.7	2

13	Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma. <i>BioMed Research International</i> , 2015 , 2015, 341430	3	34
12	Role of Conventional Karyotyping in Multiple Myeloma in the Era of Modern Treatment and FISH Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, e470-e477	2	2
11	Conventional Cytogenetics and Interphase Fluorescence In Situ Hybridization Results in Multiple Myeloma: A Turkey Laboratory Analysis of 381 Cases. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2020 , 36, 284-291	0.7	1
10	Cytogenetics in the genomic era. <i>Best Practice and Research in Clinical Haematology</i> , 2020 , 33, 101196	4.2	1
9	Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma. <i>Blood Advances</i> , 2020 , 4, 2236-2244	7.8	7
8	EVALUATION OF PLASMA CELL PROPIDIUM-IODIDE AND ANNEXIN-V INDICES: THEIR RELATION TO PROGNOSIS IN MULTIPLE MYELOMA. <i>Biomedical Papers of the Medical Faculty of the University Palacky&#x0301;, Olomouc, Czechoslovakia</i> , 2005 , 149, 271-274	1.7	5
7	Biology-Based Classification and Staging of Multiple Myeloma. 2008 , 41-56		
6	Basic Biology of Plasma Cell Dyscrasias: Focus on the Role of the Tumor Microenviroment. 2008 , 23-39		
5	Cytogenetic Abnormalities in Multiple Myeloma: The Importance of FISH and Cytogenetics. 2008 , 57-76		
4	Hematologic malignancies: correlation between morphology, phenotype,. 2008 , 125-242		
3	Observation on frequency & clinico-pathological significance of various cytogenetic risk groups in multiple myeloma: an experience from India. <i>Indian Journal of Medical Research</i> , 2016 , 144, 536-543	2.9	4
2	Plasma Cell Disorders. 1-30		0
1	Advantages and Shortcomings of FISH Tech-nology in Multiple Myeloma. 2022 , 12, 10008-10011		0